Agena at AMP 2020 - Our Workshop Speakers

Responding to the COVID-19 Pandemic – Perspectives from Clinical Laboratories Performing SARS-CoV-2 Testing

Dr Brent Zanke, Laboratory Director, Arctic Medical Laboratories

Brent Zanke is a graduate of the Universities of Manitoba (MD, 1983) and Toronto (PhD 1993) and a Fellow of the Royal College of Physicians of Canada with specialty certification in internal medicine and medical oncology. He conducted basic and translational laboratory-based research at the Ontario Cancer Institute before assuming administrative duties as Director of the Cross Cancer Institute in Edmonton, one of Canada’s two free standing cancer hospitals. He was the Provincial Head of Systemic Therapy for Cancer Care Ontario from 2002 until 2006 . Dr. Zanke also leads the multi-site Ontario tumor bio-profiling initiative of the Ontario Cancer Research Network (www.ontariotumorbank.ca). This large-scale project is part of an ongoing bio-informatics effort to organize clinical outcome measures with biologic profiles of human tumors. He also conducts large scale biomarker and genetic predictors of colon cancer risk having received funding from Genome Canada, the Canadian Cancer Society and the Ontario Ministry of Research and Innovation. He is founder and Chairman of ArcticDx, a Canadian private molecular diagnostics company where he also fills the role of Chief Medical Officer.

Email Your Question

Darryl Irwin, PhD, Vice President, Scientific Affairs, Agena Bioscience

Darryl Irwin has been leading the Scientific Affairs and Assays by Agena operations at Agena Bioscience (and its predecessor Sequenom Inc.) in Asia Pacific, and more recently in a global capacity, for 12 years. Previously, Darryl led the genotyping division at the Australian Genome Research Facility. Darryl has also held positions at the Mater Laboratory Services, a hospital-based clinical genetics laboratory and Agen Biomedical, an immuno-diagnostics manufacturer. Darryl has a PhD from the University of Queensland in Non-Invasive Prenatal Testing (NIPT) and a BSc in Biotechnology from the Queensland University of Technology. Darryl has authored more than 20 publications, numerous book chapters, and holds several patents.

Email Your Question

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

Prof. Dr. Ed Schuuring, Professor of Molecular Oncological Pathology, University Medical Center Groningen

Ed Schuuring studied Medical Biology at the University of Amsterdam (cum laude). In 1991 he received a staff position as a senior research scientist at the Department of Pathology at the Leiden University Medical Center. In 2001 Ed Schuuring continued his career at the Department of Pathology at the University Medical Center Groningen and was appointed as full professor in Molecular Oncological Pathology. His latest research interest is the detection and monitoring of tumor response and resistance to TKI treatment and immunotherapy in GIST and NSCLC. He is an active member of the Dutch Society of Pathology (chair of the section of Clinical, Molecular and Experimental Pathology), American Association of Cancer Research, the Association of Molecular Pathology, American Society of Clinical Oncology, European Society of Pathology, Dutch Society of Oncology, among others.

Email Your Question

Darryl Irwin, PhD, Vice President, Scientific Affairs, Agena Bioscience

Email Your Question

Meet Our AMP 2020 Workshop Presenters

About Agena Bioscience

Connect